Literature DB >> 6143785

Gonococcal pili. Primary structure and receptor binding domain.

G K Schoolnik, R Fernandez, J Y Tai, J Rothbard, E C Gotschlich.   

Abstract

The complete amino acid sequence of pilin from gonococcal strain MS11 and the sequence of constant and variable regions from strain R10 pilin have been determined in order to elucidate the structural basis for adherence function, antigenic diversity, and polymeric structure. The MS11 pilin sequence consists of 159 amino acids in a single polypeptide chain with two cysteines in disulfide linkage and serine-bonded phosphate residues. TC-2 (31-111), a soluble monomeric pilus peptide prepared by arginine-specific digestion, bound human endocervical, but not buccal or HeLa cells and therefore is postulated to encompass the receptor binding domain. Variable regions of CNBr-3 appear to confer antigenic diversity and comprise segments in which changes in the position of charged residues occur in hydrophilic, beta-turns. Residues 2-21 and 202-221 of gonococcal pilins and lower eucaryotic actins, respectively, exhibit 50% homology. When these residues are arranged at intervals of 100 degrees of arc on "helical wheels," the identical amino acids comprise a hydrophobic face on one side of the helix. This observation, the hydrophobic character of this region and the tendency for TC-1 (residues 1-30) to aggregate in water, suggest that this stretch interacts with other subunits to stabilize polymeric structure.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6143785      PMCID: PMC2187295          DOI: 10.1084/jem.159.5.1351

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  40 in total

1.  Use of helical wheels to represent the structures of proteins and to identify segments with helical potential.

Authors:  M Schiffer; A B Edmundson
Journal:  Biophys J       Date:  1967-03       Impact factor: 4.033

2.  Carboxypeptidase from yeast. Large scale preparation and the application to COOH-terminal analysis of peptides and proteins.

Authors:  R Hayashi; S Moore; W H Stein
Journal:  J Biol Chem       Date:  1973-04-10       Impact factor: 5.157

3.  Conformational parameters for amino acids in helical, beta-sheet, and random coil regions calculated from proteins.

Authors:  P Y Chou; G D Fasman
Journal:  Biochemistry       Date:  1974-01-15       Impact factor: 3.162

Review 4.  Mechanism of lysozyme action.

Authors:  D M Chipman; N Sharon
Journal:  Science       Date:  1969-08-01       Impact factor: 47.728

Review 5.  The structure, function, synthesis and genetic control of bacterial pili and a molecular model for DNA and RNA transport in gram negative bacteria.

Authors:  C C Brinton
Journal:  Trans N Y Acad Sci       Date:  1965-06

6.  Structural studies on rabbit skeletal actin. I. Isolation and characterization of the peptides produced by cyanogen bromide cleavage.

Authors:  R S Adelstein; W M Kuehl
Journal:  Biochemistry       Date:  1970-03-17       Impact factor: 3.162

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

8.  The human fallopian tube: a laboratory model for gonococcal infection.

Authors:  M E Ward; P J Watt; J N Robertson
Journal:  J Infect Dis       Date:  1974-06       Impact factor: 5.226

9.  Studies on gonococcus infection. I. Pili and zones of adhesion: their relation to gonococcal growth patterns.

Authors:  J Swanson; S J Kraus; E C Gotschlich
Journal:  J Exp Med       Date:  1971-10-01       Impact factor: 14.307

10.  Studies on gonococcus infection. IV. Pili: their role in attachment of gonococci to tissue culture cells.

Authors:  J Swanson
Journal:  J Exp Med       Date:  1973-03-01       Impact factor: 14.307

View more
  65 in total

Review 1.  Gonococcal vaccines.

Authors:  E C Tramont
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

2.  Neisseria gonorrhoeae PilV, a type IV pilus-associated protein essential to human epithelial cell adherence.

Authors:  H C Winther-Larsen; F T Hegge; M Wolfgang; S F Hayes; J P van Putten; M Koomey
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

3.  Restriction fragment length polymorphism in the cytadhesin P1 gene of human clinical isolates of Mycoplasma pneumoniae.

Authors:  S F Dallo; J R Horton; C J Su; J B Baseman
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

4.  Discovery of a novel protein modification: alpha-glycerophosphate is a substituent of meningococcal pilin.

Authors:  E Stimson; M Virji; S Barker; M Panico; I Blench; J Saunders; G Payne; E R Moxon; A Dell; H R Morris
Journal:  Biochem J       Date:  1996-05-15       Impact factor: 3.857

5.  Mutational analysis of plasmid R64 thin pilus prepilin: the entire prepilin sequence is required for processing by type IV prepilin peptidase.

Authors:  T Horiuchi; T Komano
Journal:  J Bacteriol       Date:  1998-09       Impact factor: 3.490

6.  Globoside-specific adhesins of uropathogenic Escherichia coli are encoded by similar trans-complementable gene clusters.

Authors:  B Lund; F P Lindberg; M Båga; S Normark
Journal:  J Bacteriol       Date:  1985-06       Impact factor: 3.490

7.  Cloning and expression of the pilin gene of Pseudomonas aeruginosa PAK in Escherichia coli.

Authors:  M S Strom; S Lory
Journal:  J Bacteriol       Date:  1986-02       Impact factor: 3.490

8.  Cloning and sequencing of a Moraxella bovis pilin gene.

Authors:  C F Marrs; G Schoolnik; J M Koomey; J Hardy; J Rothbard; S Falkow
Journal:  J Bacteriol       Date:  1985-07       Impact factor: 3.490

9.  Immunochemical characterization of P pili from invasive Escherichia coli.

Authors:  J Hanley; I E Salit; T Hofmann
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

10.  Identification, localization, and distribution of the PilT protein in Neisseria gonorrhoeae.

Authors:  L Brossay; G Paradis; R Fox; M Koomey; J Hébert
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.